Back Login for AI Analysis

    VKTX (STOCKS)

    Viking Therapeutics, Inc

    $32.280000
    +3.530000 (+12.28%)
    Prev close: $28.750000
    Company Information
    Exchange
    XNAS
    Sector
    Health Technology
    Industry
    Pharmaceuticals: Major
    CEO
    Brian Lian
    Asset Type
    stocks
    Website
    Visit
    Fundamentals
    Market Cap
    $3,265.79M
    Employees
    51
    P/E (TTM)
    -13.48
    P/B (TTM)
    4.50
    Dividend Yield
    Technical Indicators
    SMA 10
    SMA 20
    SMA 50
    EMA 9
    EMA 21
    RSI
    MACD State
    Recent News

    No recent news found for this ticker.

    Financial Statements
    TTM (Sep 2025)
    Revenues $0.00
    Operating Expenses $274.84M
    Research and Development $222.48M
    Other Operating Expenses $52.36M
    Operating Income/Loss -$274.84M
    Income/Loss From Continuing Operations After Tax -$237.39M
    Income/Loss From Continuing Operations Before Tax -$237.39M
    Net Income/Loss -$237.39M
    Net Income/Loss Attributable To Noncontrolling Interest $0.00
    Net Income/Loss Attributable To Parent -$237.39M
    Net Income/Loss Available To Common Stockholders, Basic -$237.39M
    Participating Securities, Distributed And Undistributed Earnings/Loss, Basic $0.00
    Preferred Stock Dividends And Other Adjustments $0.00
    Basic Earnings Per Share -$2.12
    Diluted Earnings Per Share -$2.12
    Basic Average Shares 112,992,000
    Diluted Average Shares 112,992,000
    Assets $739.42M
    Current Assets $738.70M
    Noncurrent Assets $712.00K
    Liabilities $26.39M
    Current Liabilities $26.07M
    Accounts Payable $4.41M
    Other Current Liabilities $21.65M
    Noncurrent Liabilities $318.00K
    Equity $713.03M
    Equity Attributable To Noncontrolling Interest $0.00
    Equity Attributable To Parent $713.03M
    Liabilities And Equity $739.42M
    Net Cash Flow From Operating Activities -$224.58M
    Net Cash Flow From Operating Activities, Continuing -$224.58M
    Net Cash Flow From Investing Activities $272.36M
    Net Cash Flow From Investing Activities, Continuing $272.36M
    Net Cash Flow From Financing Activities $2.34M
    Net Cash Flow From Financing Activities, Continuing $2.34M
    Net Cash Flow $50.12M
    Net Cash Flow, Continuing $50.12M
    Comprehensive Income/Loss -$238.65M
    Comprehensive Income/Loss Attributable To Noncontrolling Interest $0.00
    Comprehensive Income/Loss Attributable To Parent -$238.65M
    Other Comprehensive Income/Loss -$1.26M